Avalo Therapeutics (AVTX)
(Delayed Data from NSDQ)
$9.63 USD
-0.14 (-1.39%)
Updated Oct 7, 2024 03:55 PM ET
After-Market: $9.96 +0.33 (3.40%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$9.63 USD
-0.14 (-1.39%)
Updated Oct 7, 2024 03:55 PM ET
After-Market: $9.96 +0.33 (3.40%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Zacks News
Is Annexon (ANNX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Annexon, Inc. (ANNX) and Avalo Therapeutics, Inc. (AVTX) have performed compared to their sector so far this year.
Is Avalo Therapeutics (AVTX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Avalo Therapeutics, Inc. (AVTX) and Annexon, Inc. (ANNX) have performed compared to their sector so far this year.
Avalo Therapeutics (AVTX) Surges 270% in a Week: Here's Why
by Zacks Equity Research
Avalo (AVTX) surges on adding a new pipeline drug, which has its origins at Eli Lilly. Alongside the acquisition, it also secured funding to continue operations beyond 2027.
Will Avalo Therapeutics, Inc. (AVTX) Report Negative Q4 Earnings? What You Should Know
by Zacks Equity Research
Avalo Therapeutics (AVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Foghorn Therapeutics Inc. (FHTX) delivered earnings and revenue surprises of 27.85% and 17.59%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Avalo (AVTX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Devoid of marketed drugs, investors will focus on Avalo Therapeutics' (AVTX) lead pipeline drug when it reports fourth-quarter earnings results.
New Strong Buy Stocks for January 3rd
by Zacks Equity Research
GWRS, SRPT, AVTX, NTGR and PAY have been added to the Zacks Rank #1 (Strong Buy) List on January 3, 2024.
New Strong Buy Stocks for December 14th
by Zacks Equity Research
MUSA, AVTX, ANIK, CARG and WES have been added to the Zacks Rank #1 (Strong Buy) List on December 14, 2023.
Travere (TVTX) Up on Latest Portfolio Updates & Reorganization
by Zacks Equity Research
Travere (TVTX) to submit an sNDA to the FDA to convert the accelerated approval for Filspari to full approval for IgAN in first-quarter 2024. The company is implementing a strategic reorganization to cut costs. Stock rises.
ImmunoGen (IMGN) Gets FDA Priority Review for Elahere sBLA
by Zacks Equity Research
The FDA grants priority review to ImmunoGen's (IMGN) sBLA to convert the accelerated approval for Elahere to full approval for treating platinum-resistant ovarian cancer. A decision is due on Apr 5, 2024.
New Strong Buy Stocks for November 27th
by Zacks Equity Research
VVI, AVTX, RYI, TM and HIBB have been added to the Zacks Rank #1 (Strong Buy) List on November 27, 2023.
New Strong Buy Stocks for November 21st
by Zacks Equity Research
AQST, RBT, HARP, VVI and AVTX have been added to the Zacks Rank #1 (Strong Buy) List on November 21, 2023.
Avalo (AVTX) Up 45% on Deal to Divest Certain Pipeline Drugs
by Zacks Equity Research
Avalo (AVTX) will receive an upfront payment of $150,000 on selling three compounds to AUG Therapeutics. The company is also eligible to receive milestone payments of up to $45 million.
Avalo Therapeutics, Inc. (AVTX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Avalo Therapeutics, Inc. (AVTX) delivered earnings and revenue surprises of 34.44% and 35.70%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Avalo (AVTX) Fails to Meet Goal in Asthma Study, Stock Down 89%
by Zacks Equity Research
Avalo (AVTX) announces that it failed to meet the primary endpoint in its mid-stage poorly controlled non-eosinophilic asthma study. The stock falls 89% on Monday following the news.
Avalo Therapeutics, Inc. (AVTX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Avalo Therapeutics, Inc. (AVTX) delivered earnings and revenue surprises of 12.37% and 52.50%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Avalo Therapeutics, Inc. (AVTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Avalo Therapeutics, Inc. (AVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pacira's (PCRX) sNDA for Exparel Accepted for FDA Review
by Zacks Equity Research
The FDA accepts Pacira's (PCRX) sNDA filing, which seeks to expand the label of its pain drug Exparel to include both sciatic and femoral nerve blocks. A final decision is expected by November 2023.
Novo Nordisk (NVO) Meets Semaglutide Higher Dosage Study Goal
by Zacks Equity Research
Novo Nordisk (NVO) announces positive top-line results from its phase III increased dosage study of semaglutide, 25 mg and 50 mg, for the treatment of patients with type II diabetes.
Roche (RHHBY) & Lilly to Co-Develop Alzheimer's Detection Device
by Zacks Equity Research
Roche (RHHBY) and Lilly announce a collaboration deal to support the development of the former's early diagnosis device for Alzheimer's Disease.
Altimmune (ALT) Stock Down Despite Positive Obesity Study Data
by Zacks Equity Research
Altimmune (ALT) reports positive interim analysis data from a phase II obesity study of pemvidutide. However, the stock dropped about 55% likely due to concerns regarding the high discontinuation rate.
ACER's Stock Down on Failure of Phase II Study, Cash Updates
by Zacks Equity Research
ACER announces the failure of its phase IIa study of ACER-801 to treat vasomotor symptoms associated with menopause, along with its extinguishing cash runway. Stock down.
Pfizer's (PFE) COVID-19 Drug Paxlovid Gets FDA Panel Vote
by Zacks Equity Research
FDA's Antimicrobial Drugs Advisory Committee (AMDAC) votes 16 to 1 for Pfizer's Paxlovid for the treatment of mild-to-moderate COVID-19 in adult patients at high risk of hospitalization or death.
Catalyst's (CPRX) Q4 Earnings & Sales Top, Boosted by Firdapse
by Zacks Equity Research
Catalyst Pharmaceuticals (CPRX) reports better-than-expected financial performance as it beats both earnings and revenue estimates. Firdapse sales continue to grow year over year.
Verve Therapeutics (VERV) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Verve Therapeutics (VERV) delivered earnings and revenue surprises of -5.33% and 81.42%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?